Boston Scientific Competitors

Abbott Laboratories (NYSE:ABT) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, risk and profitability.

Risk & Volatility

Abbott Laboratories has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Abbott Laboratories and Boston Scientific, as provided by MarketBeat.

Abbott Laboratories presently has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Boston Scientific has a consensus target price of $43.80, suggesting a potential upside of 31.41%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Abbott Laboratories.

Profitability

This table compares Abbott Laboratories and Boston Scientific's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Abbott Laboratories and Boston Scientific's gross revenue, earnings per share (EPS) and valuation.

Boston Scientific has lower revenue, but higher earnings than Abbott Laboratories. Boston Scientific is trading at a lower price-to-earnings ratio than Abbott Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.9% of Abbott Laboratories shares are held by institutional investors. Comparatively, 82.7% of Boston Scientific shares are held by institutional investors. 1.7% of Abbott Laboratories shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Boston Scientific beats Abbott Laboratories on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Medtronic, as reported by MarketBeat.

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Medtronic has a consensus target price of $118.1538, indicating a potential upside of 6.47%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Medtronic.

Profitability

This table compares Boston Scientific and Medtronic's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Boston Scientific and Medtronic's revenue, earnings per share and valuation.

Medtronic has higher revenue and earnings than Boston Scientific. Boston Scientific is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 79.9% of Medtronic shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 0.5% of Medtronic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Boston Scientific beats Medtronic on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Stryker (NYSE:SYK) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Stryker has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Stryker, as reported by MarketBeat.

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Stryker has a consensus target price of $221.44, indicating a potential downside of 4.97%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Stryker.

Profitability

This table compares Boston Scientific and Stryker's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Boston Scientific and Stryker's revenue, earnings per share and valuation.

Boston Scientific has higher earnings, but lower revenue than Stryker. Boston Scientific is trading at a lower price-to-earnings ratio than Stryker, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 71.0% of Stryker shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 6.8% of Stryker shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Boston Scientific beats Stryker on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Risk & Volatility

Boston Scientific has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.

Institutional and Insider Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 86.9% of Intuitive Surgical shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Boston Scientific and Intuitive Surgical's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current recommendations and price targets for Boston Scientific and Intuitive Surgical, as reported by MarketBeat.

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Intuitive Surgical has a consensus target price of $718.2778, indicating a potential downside of 0.11%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Boston Scientific is more favorable than Intuitive Surgical.

Earnings & Valuation

This table compares Boston Scientific and Intuitive Surgical's revenue, earnings per share and valuation.

Boston Scientific has higher revenue and earnings than Intuitive Surgical. Boston Scientific is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Intuitive Surgical on 8 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Becton, Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Boston Scientific has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Becton, Dickinson and has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500.

Insider & Institutional Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 74.4% of Becton, Dickinson and shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 0.1% of Becton, Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Becton, Dickinson and's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Boston Scientific and Becton, Dickinson and, as reported by MarketBeat.

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Becton, Dickinson and has a consensus target price of $280.2857, indicating a potential upside of 22.67%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than Becton, Dickinson and.

Earnings and Valuation

This table compares Boston Scientific and Becton, Dickinson and's revenue, earnings per share (EPS) and valuation.

Boston Scientific has higher earnings, but lower revenue than Becton, Dickinson and. Boston Scientific is trading at a lower price-to-earnings ratio than Becton, Dickinson and, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Becton, Dickinson and on 10 of the 15 factors compared between the two stocks.

Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Volatility & Risk

Boston Scientific has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

82.7% of Boston Scientific shares are owned by institutional investors. Comparatively, 79.7% of Edwards Lifesciences shares are owned by institutional investors. 0.7% of Boston Scientific shares are owned by insiders. Comparatively, 1.5% of Edwards Lifesciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Boston Scientific and Edwards Lifesciences' net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of current ratings and price targets for Boston Scientific and Edwards Lifesciences, as reported by MarketBeat.

Boston Scientific presently has a consensus target price of $43.80, indicating a potential upside of 31.41%. Edwards Lifesciences has a consensus target price of $87.7222, indicating a potential upside of 3.57%. Given Boston Scientific's stronger consensus rating and higher probable upside, equities analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Earnings and Valuation

This table compares Boston Scientific and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Summary

Boston Scientific beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.